Agency of the United States Department of Health and Human Services
POPULARITY
Categories
357 episodes with fda
281 episodes with fda
183 episodes with fda
247 episodes with fda
229 episodes with fda
126 episodes with fda
183 episodes with fda
112 episodes with fda
147 episodes with fda
150 episodes with fda
273 episodes with fda
183 episodes with fda
178 episodes with fda
185 episodes with fda
53 episodes with fda
82 episodes with fda
75 episodes with fda
90 episodes with fda
65 episodes with fda
62 episodes with fda
135 episodes with fda
55 episodes with fda
70 episodes with fda
107 episodes with fda
107 episodes with fda
61 episodes with fda
68 episodes with fda
36 episodes with fda
96 episodes with fda
44 episodes with fda
50 episodes with fda
65 episodes with fda
44 episodes with fda
42 episodes with fda
105 episodes with fda
43 episodes with fda
64 episodes with fda
50 episodes with fda
47 episodes with fda
51 episodes with fda
61 episodes with fda
97 episodes with fda
78 episodes with fda
41 episodes with fda
38 episodes with fda
59 episodes with fda
64 episodes with fda
56 episodes with fda
55 episodes with fda
97 episodes with fda
73 episodes with fda
59 episodes with fda
49 episodes with fda
99 episodes with fda
Jackie takes a well earned deep breath following the completion of the Dim the Lights tour, rails against the glorification of tinned fish, and advises against combining bodily fluid colors in an outfit.Thanks for supporting my sponsors:Home Chef: For a limited time, get 50% off and free shipping for your first box. Plus free dessert for life at www.HomeChef.com/BIBLENutrafol: For a limited time, get $10 off your first month's subscription and free shipping at www.nutrafol.com/biblePique: Get up to 20% off for life, plus a complimentary gift at www.PiqueLife.com/BIBLEAddyi: Check out the FDA-approved treatment for certain premenopausal women who are bothered by low libido and want their sex drive back at www.Addyi.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
The FDA is planning to remove the “black box” warning from many hormone treatments for menopause -- a major shift that could change care for millions of women in this country. On this week's Paging Dr. Gupta, we break down what who this treatment could help and what you still need to know about its risks. This episode was produced by Jennifer Lai with assistance from Kyra Dahring and Leying Tang. Showrunner: Amanda Sealy Senior Producer: Dan Bloom Technical Director: Dan Dzula Executive Producer: Steve Lickteig Learn more about your ad choices. Visit podcastchoices.com/adchoices
In this episode of The President's Daily Brief: Newly uncovered emails reveal Jeffrey Epstein's sprawling network of foreign contacts — and his extraordinary claims that he was feeding Russian associates insight into Donald Trump's policy decisions. Poland deploys security forces after a critical rail line to Ukraine is blown up in what officials are calling a suspected act of sabotage. Plus — thousands of demonstrators in Mexico City clash with police during protests over cartel violence and government inaction. And in today's Back of the Brief — a notorious Ecuadorian drug kingpin who faked his own death has finally been captured in Spain, ending four years on the run. To listen to the show ad-free, become a premium member of The President's Daily Brief by visiting https://PDBPremium.com. Please remember to subscribe if you enjoyed this episode of The President's Daily Brief. YouTube: youtube.com/@presidentsdailybrief Rugiet: Ready to give Rugiet a try? Get 15% off your first order by going to http://rugiet.com/PDB and using code PDB. Rugiet prescriptions are compounded medications, available only if prescribed following an online consultation with a licensed clinician. Compounded drugs can be prescribed by federal law, but are not FDA-approved and have not been reviewed by the FDA for safety, effectiveness, or manufacturing. Individual results may vary. Full safety information available at https://Rugiet.com Lean: Visit https://BrickhouseSale.comfor 30% off StopBox: Not only do you get 10% Off your entire order when you use code PDB10 at https://stopboxusa.com/PDB10, but they are also giving you Buy One Get One Free for their StopBox Pro. #stopboxpod Learn more about your ad choices. Visit megaphone.fm/adchoices
In this episode of The PDB Afternoon Bulletin: Russia's oil sector is taking heavy hits on two fronts. Ukrainian drones are striking deep inside the country, while new U.S. sanctions are cutting off key buyers in India and China. We'll explain why this dual pressure is becoming a serious problem for Moscow's war economy. Germany is preparing to lift its freeze on arms exports to Israel, saying the Gaza ceasefire has stabilized enough to reverse restrictions imposed during the height of the conflict. Please remember to subscribe if you enjoyed this episode of The President's Daily Brief. YouTube: youtube.com/@presidentsdailybrief Rugiet: Ready to give Rugiet a try? Get 15% off your first order by going to http://rugiet.com/PDB and using code PDB. Rugiet prescriptions are compounded medications, available only if prescribed following an online consultation with a licensed clinician. Compounded drugs can be prescribed by federal law, but are not FDA-approved and have not been reviewed by the FDA for safety, effectiveness, or manufacturing. Individual results may vary. Full safety information available at https://Rugiet.com Lean: Visit https://BrickhouseSale.comfor 30% off StopBox: Not only do you get 10% Off your entire order when you use code PDB10 at https://stopboxusa.com/PDB10, but they are also giving you Buy One Get One Free for their StopBox Pro. #stopboxpod Learn more about your ad choices. Visit megaphone.fm/adchoices
What if everything you've been told about menopause is wrong? In this episode, I sit down with Dr. Mary Claire Haver — board-certified OB/GYN and leading menopause expert — to unpack the science reshaping women's health. We break down the FDA's recent removal of the 22-year black box warning on hormone therapy, why only 4% of women use HRT today, and how fear and misinformation have shaped decades of care. Dr. Haver also dives into the rise of menopause “biohacks,” from NAD and PRP to the fundamentals that truly move the needle: sleep, strength training, and metabolic health. Her message is simple: Menopause isn't a disease — it's a transition, and you deserve informed, evidence-based support. If you've ever felt dismissed or confused during midlife changes, this conversation will give you clarity, confidence, and the science to advocate for yourself. Follow Dr. Haver:Instagram: @drmaryclaireTikTok: @drmaryclaireWebsite: The Pause LifePre-order The New Perimenopause, set to release on April 7, 2026: https://thepauselife.com/pages/the-new-perimenopause-bookListen to Dr. Haver's podcast, unPAUSED, here: https://thepauselife.com/pages/the-unpaused-podcast *** Subscribe to The Neuro Experience for more conversations at the intersection of brain science and performance. I'm committed to bringing you evidence-based insights that you can apply to your own health journey. *** A huge thank you to my sponsors for supporting this episode. Check them out and enjoy exclusive discounts: TroscriptionsGive it a try at https://www.troscriptions.com/NEURO or enter NEURO at checkout for 10% off your first order. TimelineHead to https://www.timeline.com/neuro to get started. Branch BasicsHead to https://www.branchbasics.com and use code NEURO for 15% off. Hollow SocksFor a limited time Hollow Socks is having a Buy 3, Get 3 Free Sale. Head to https://www.ollowsocks.com today to check it out. Jones Road BeautyUse code NEURO at https://www.jonesroadbeauty.com to get a free Cool Gloss with your first purchase. *** I'm Louisa Nicola — clinical neurophysiologist — Alzheimer's prevention specialist — founder of Neuro Athletics. My mission is to translate cutting-edge neuroscience into actionable strategies for cognitive longevity, peak performance, and brain disease prevention. If you're committed to optimizing your brain — reducing Alzheimer's risk — and staying mentally sharp for life, you're in the right place. Stay sharp. Stay informed. Join thousands who subscribe to the Neuro Athletics Newsletter → https://bit.ly/3ewI5P0 Instagram: https://www.instagram.com/louisanicola_/ Twitter : https://twitter.com/louisanicola_***Topics discussed: 00:00 – Intro 01:55 – The FDA removed the “black box” warning for HRT 05:16 – The Social Media Effect on Menopause Education 07:54 – How Doctors Historically Dismiss Women's Symptoms 11:12 – Why So Many Women Get Antidepressants Instead of HRT 14:07 – Life Stress vs Hormone-Driven Symptoms 16:48 – The Timing Hypothesis / Critical Window Explained 19:06 – Why Modern RCTs Aren't Happening 20:10 – Proven Benefits: Bone Health & Osteoporosis Prevention 21:35 – HRT, Dementia, and Brain Health: What the Data Actually Shows 23:16 – Environmental Toxins, Brain Health & Midlife Risk Factors 25:24 – How the Internet Distorts Menopause Education 27:10 – The “Brain Eating Itself” Debate: The Real Science 30:09 – What Brain Fog Really Is During Perimenopause 32:24 – Why High-Functioning Women Struggle the Most 34:03 – Breast Cancer Risk: What the WHI Actually Found 35:00 – Why Sleep Is the First Line of Treatment Learn more about your ad choices. Visit megaphone.fm/adchoices
If you've ever hit a breaking point, the kind that forces you to stop pretending you're fine, this episode is medicine. Emily Fletcher sits down with actress and creative force Tati Gabrielle (You, Chilling Adventures of Sabrina, Kaleidoscope) to explore how pain becomes power when you're willing to meet it head-on. From depression in Atlanta to an identity unraveling to discovering a spiritual practice that rebuilt her from the inside out, Tati shares the raw moments that became her initiation into authenticity. This conversation isn't about bypassing pain, it's about alchemizing it. Turning the collapse into clarity. Turning the wound into wisdom. Turning the struggle into strength. In this episode, we explore: • How to recognize when pain is trying to redirect you • The morning ritual that helped Tati rebuild her life • The difference between numbing pain and transforming it • Why meditation can be a portal for emotional alchemy • The “mind palace” technique she used to rewire her future • How intuition becomes louder when you stop abandoning yourself • What inner child healing actually looks like in daily life • A more empowered way to relate to fate, free will, and resilience Timestamps: • [02:01] When everything broke open — Tati's turning point and the moment pain became her invitation inward. • [06:26] The 7 a.m. ritual that saved her — The simple, self-created practice that pulled her out of depression. • [10:06] Anxiety vs. soul alignment — How she learned to read her body and separate fear from intuition. • [12:18] The “red carpet” vision — The emotional anchor that fueled her transformation and early manifestation wins. • [17:38] The power pivot — How her internal shift created rapid external change (manager, agent, bookings). • [24:38] The body map of intuition — The clearest explanation of where intuition lives vs. where anxiety lives. • [32:49] Life as a video game — A reframe for navigating pain, destiny, and empowerment with play instead of pressure. • [40:57] Mini-resets that regulate the nervous system — The exact micro-practices Tati uses when she spirals. • [48:30] Inside the darkest moments — How she navigates panic, bipolar swings, and the instinct that brings her back. • [53:06] Acting as devotion — How she channels characters as real souls — and why creativity can be healing. Guest Links: • Follow Tati → @tatigabrielle • Watch Tati's work → Netflix: You, Chilling Adventures of Sabrina, Kaleidoscope • IMDb → imdb.com/name/nm5354727 More from Emily & Ziva: • Join Ziva Magic: makemagic.zivameditation.com • Learn Ziva Meditation: preview.zivameditation.com • Free Masterclass: learn.zivameditation.com • Get 15% off with promo code WHYTHIS: whythis.zivameditation.com • Follow on Instagram: @zivameditation • Visit upgradedformulas.com/emily and use code EMILY for 20% off everything at UpgradedFormulas.com. These statements have not been evaluated by the FDA. Products are not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider if pregnant/nursing, on medication, or have a medical condition.
When conventional revascularization fails, can deep venous arterialization offer a new lifeline to limb salvage? Dr. Lucas Ferrer Cardona, vascular surgeon at Ascension and Dr. Miguel Montero Baker, vascular surgeon and medical director at HOPE Clinical Innovation Center join host Dr. Sabeen Dhand for an insightful discussion on deep venous arterialization (DVA). --- This podcast is supported by: RADPAD® Radiation Protectionhttps://www.radpad.com/ --- SYNPOSIS The doctors discuss the progression of deep venous arterialization, highlighting the benefits of open, endovascular, and hybrid approaches. They draw on their personal experiences to share key technical nuances and explore new devices such as the Aveera Boomerang device. They emphasize the critical role of patient selection, family support, and close postoperative surveillance, including weekly wound assessments and monthly ultrasound evaluations. Although currently FDA-approved for no-option chronic limb-threatening ischemia (CLTI), Dr. Baker notes that deep venous arterialization may hold promise even for patients earlier in the disease course.The episode concludes by exploring future directions for deep venous arterialization, highlighting the ongoing need for research to advance limb preservation. --- TIMESTAMPS 00:00 - Introduction03:15 - The Inspiration Behind Their Podcast10:05 - Challenges and Success Stories in Vascular Surgery10:29 - Exploring Deep Venous Arterialization (DVA)25:16 - Hybrid Approaches and Patient Outcomes32:06 - Evolution of Endovascular Techniques37:33 - Patient Selection and Criteria38:52 - Understanding the Biology of Procedures43:57 - Exploring New Techniques and Devices58:52 - Challenges and Considerations01:01:51 - Final Thoughts --- RESOURCES Hybrid superficial venous arterialization and endovascular deep venous arterializationhttps://pubmed.ncbi.nlm.nih.gov/37404577/ Transcatheter Arterialization of Deep Veins in Chronic Limb-Threatening Ischemiahttps://www.nejm.org/doi/full/10.1056/NEJMoa2212754
Nathan Jones, CEO of Xlear, Inc., details the benefits of xylitol in dental and respiratory health products such as nasal sprays and chewing gums under the Spry brand. Nathan advocates for the FDA to allow anti-cavity claims for xylitol and other compounds despite the current monopoly of fluoride in such claims. They question the efficacy and potential downsides of fluoride, and explore alternative dental health interventions. The episode also covers xylitol's role in preventing tooth decay, respiratory health benefits during the COVID-19 pandemic, and ongoing legal challenges with the FTC. Discussions highlight the potential implications of oral health on systemic diseases like cardiovascular disease and Parkinson's, and emphasize the importance of nasal hygiene alongside dental care.
Dr. Hoffman continues his conversation with Nathan Jones, CEO of Xlear, Inc.
Richard Pazdur took the top job at FDA's Center for Drug Evaluation and Research after receiving vows that he would be leading CDER free from political interference. On the latest BioCentury This Week podcast, BioCentury's analysts discuss the issues that could prove to be flashpoints between Pazdur and the heads of FDA and HHS, including personnel, RSV mAbs, puberty blockers and SSRIs.BioCentury's analysts assess bispecific innovation at the annual meeting of the Society for Immunotherapy of Cancer (SITC) and the growing field of companies pursuing RNAi, many of which have multiple unpartnered assets. Also featured in this week's episode: new funds from European VCs Medicxi and Sofinnova Partners, FDA's new plausible mechanism pathway and the Trump administration's “most favored nation” drug-pricing plan, which is turning out to be much more less onerous to drug companies than its original description suggested. This episode of the BioCentury This Week podcast is brought to you by Voyager Therapeutics.View full story: https://www.biocentury.com/article/657631#RNAiTherapeutics #BispecificAntibodies #CD3TCellEngagers #MechanismOfAction #ImmunoOncology #PlausibleMechanismPathway #RegulatoryScience #ClinicalTranslation00:01 - Sponsor Message: Voyager Therapeutics 03:08 - FDA's Richard Pazdur13:08 - Plausible Mechanism Pathway19:30 - Most Favored Nation23:12 - Takeaways from SITC28:05 - RNAi in China33:21 - European VCsTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text
To kick off Food Safety Awareness Month, I'll be joined by Chef Keith Norman—ServSafe Instructor, Allergen Awareness Trainer, and Food Safety Manager/Assistant Executive Chef at South Point Hotel, Casino & Spa—on Eating at a Meeting Podcast LIVE. Keith lives and breathes safe dining, from the back-of-house kitchen line to the banquet floor where thousands of guests are served every day. And right now, food safety is in the headlines.
Process innovation in the pharmaceutical industry is never easy, but its best chance of success comes when companies come together to work on big problems – especially when they bring in regulators and other stakeholders. In today's episode of the pharmaphorum podcast, host Jonah Comstock speaks with Rob DiCicco, vice president of portfolio management at TransCelerate Biopharma, a membership organisation where big pharma companies work together to innovate around the discovery, development, and manufacturing of new drugs. DiCicco gives an update on TransCelerate's work with pragmatic trials and the group's meetings last year with the FDA. He discusses what pragmatic trials are and how they can improve the efficiency of clinical research, as well as describing the work that was done at the meeting last year and the report that's come out of it. He also gets into next steps, how the new administration has and hasn't affected the work TransCelerate is doing with the FDA, and the role TransCelerate plays in taking these recommendation and putting them into practice. Tune in to learn how the pharma industry is working together to change the way clinical trials are done.
The FDA belatedly liberates women's hormone replacement; Beta-blockers now deemed passé for routine heart attack aftercare; After most breast cancer surgery, adjuvant radiation brings no survival benefits; Can you drink caffeinated coffee if you have atrial fibrillation? Ignore frequent falls without attention to balance and stability training at your peril; Is it reasonable to contemplate a knee replacement surgery at 88?
In this powerful episode of The MisFitNation, host Rich LaMonica welcomes Dr. Eugene Lipov — physician, researcher, and the world's leading expert on using Stellate Ganglion Block (SGB) to treat post-traumatic stress. Dr. Lipov pioneered the use of SGB for trauma recovery in 2006, adapting a decades-old FDA-approved procedure into a breakthrough therapy for PTSD. He later developed the Dual Sympathetic Reset (DSR) protocol, which has helped thousands experience rapid and life-changing relief. Motivated by his own family's experience with trauma, Dr. Lipov is also a global advocate for redefining PTSD as Post-Traumatic Stress Injury (PTSI) — a term that removes stigma and reflects the biological nature of the condition. His work has been featured in The Wall Street Journal, USA Today, Fox National News, NBC, and numerous medical journals. He has testified before Congress, worked with military organizations worldwide, and continues to push trauma treatment into a new era of science-backed innovation. Learn more at DrEugeneLipov.com http://thegodshotbook.com
En este episodio de Micro Mundos analizamos el Acuerdo Marco Comercial entre la Argentina y los Estados Unidos, un entendimiento que todavía no es un tratado final, pero que redefine la relación bilateral: apertura acelerada de mercados, reconocimiento automático de estándares de la FDA, reglas de inversión, propiedad intelectual, comercio digital y cooperación en seguridad económica. ¿Quién gana más? ¿Qué sectores argentinos quedan expuestos? ¿Y qué implica para el Mercosur?Además, abordamos dos debates internos que marcaron la semana:• El rumor sobre la eliminación del Monotributo y el impacto inmediato que tendría sobre 4,5 millones de contribuyentes.• El cruce entre el presidente Javier Milei y el economista Emanuel Alvarez Agis, que volvió a encender la discusión sobre impuestos, formalidad y el rumbo económico.• Y el regreso de un fantasma histórico: la posibilidad de una reforma constitucional impulsada desde la Casa Rosada, con ideas que incluyen ampliar a seis años el mandato presidencial, eliminar la figura del vicepresidente y reducir el tamaño del Congreso.
In this episode of The Health Revival Show, I dive into three critical topics affecting your health. First, we discuss the recent FDA decision to remove the black box warning on hormone replacement therapy (HRT), shedding light on the implications for women's health. Next, I tackle the controversial subject of flu shots, exploring their effectiveness and the factors influencing your decision to get vaccinated. Lastly, I provide actionable insights on how to recover after experiencing a stomach bug, focusing on nutrition and hydration strategies that can help restore your gut health. Join me for an informative and engaging conversation that empowers you to make informed health choices.
Microdosing GLP-1s like Ozempic and Wegovy is the latest buzz in the health world — but is it safe, effective, or even legal? In this episode, I break down the newest research, FDA updates, and expert opinions on microdosing GLP-1 medications. Learn what the science really says, what's still unknown, and why sustainable habits will always matter more than shortcuts.
THE FDA FINALLY REMOVED THE BLACK BOX WARNING on both systemic estrogen and low-dose vaginal estrogen — and it's one of the biggest wins in women's health in decades.For years, millions of women avoided hormone therapy because of outdated, frightening warnings that did NOT match the scientific evidence. This led to unnecessary suffering — from painful sex to recurrent UTIs to fear-based avoidance of safe, effective treatments.In this episode, Dr. Carolyn Moyers (Board-Certified OB/GYN + Menopause Specialist) breaks down the NEW FDA labeling, the real data on hormone therapy safety, and why vaginal estrogen is one of the safest and most life-changing treatments in menopause care.
Purple Political Breakdown - Episode DescriptionHost: Radell LewisEpisode SummaryBuckle up for this packed episode of Purple Political Breakdown! Host Radell Lewis cuts through the partisan noise to deliver nonpartisan political analysis on the week's biggest stories that mainstream media won't fully cover.This week, we're diving deep into the historic 43-day government shutdown - the longest in American history - examining its devastating $84 billion economic impact, effects on federal workers, TSA agents working without pay, and the political maneuvering that finally ended it. We'll break down why Democrats capitulated without securing ACA subsidies and what it means for Chuck Schumer's leadership.We expose the controversial Trump pardons for 2020 election challengers including Rudy Giuliani, Mark Meadows, and Sidney Powell, plus newly released Jeffrey Epstein emails that reveal disturbing connections between Trump, Epstein, and Steve Bannon - including Epstein's claim that "Trump knew about the girls."Plus: California redistricting battles and DOJ gerrymandering lawsuits, FDA's major reversal on hormone replacement therapy warnings, and our signature Good News segment featuring breakthrough cancer treatments, cholesterol cures, e-waste recycling innovations, and peanut allergy solutions.Political solutions without bias. Finding common ground in a divided America.Topics Covered: Government shutdown, federal spending, congressional politics, Trump administration, presidential pardons, Epstein scandal, political corruption, California politics, redistricting, gerrymandering, healthcare policy, FDA regulations, medical breakthroughs, gene therapy, environmental innovation, bipartisan analysisPerfect for listeners interested in: Political news, current events, government accountability, election integrity, nonpartisan commentary, purple politics, middle ground perspectives, unbiased political analysis, congressional updates, Trump news, Biden administration, Democrat vs Republican policy Join the conversation - Purple Political Breakdown airs live Wednesdays at 6:30 PM EST#Politics #NonpartisanNews #GovernmentShutdown #Trump #Congress #PoliticalPodcast #CurrentEvents #BipartisanPolitics #PurplePolitics #PoliticalAnalysisRetryStandard Resource Links & RecommendationsThe following organizations and platforms represent valuable resources for balanced political discourse and democratic participation: PODCAST NETWORKALIVE Podcast Network - Check out the ALIVE Network where you can catch a lot of great podcasts like my own, led by amazing Black voices. Link: https://alivepodcastnetwork.com/ CONVERSATION PLATFORMSHeadOn - A platform for contentious yet productive conversations. It's a place for hosted and unguided conversations where you can grow a following and enhance your conversations with AI features. Link: https://app.headon.ai/Living Room Conversations - Building bridges through meaningful dialogue across political divides. Link: https://livingroomconversations.org/ UNITY MOVEMENTSUs United - A movement for unity that challenges Americans to step out of their bubbles and connect across differences. Take the Unity Pledge, join monthly "30 For US" conversation calls, wear purple (the color of unity), and participate in National Unity Day every second Saturday in December. Their programs include the Sheriff Unity Network and Unity Seats at sports events, proving that shared values are stronger than our differences. Link: https://www.us-united.org/ BALANCED NEWS & INFORMATIONOtherWeb - An AI-based platform that filters news without paywalls, clickbait, or junk, helping you access diverse, unbiased content. Link: https://otherweb.com/ VOTING REFORM & DEMOCRACYEqual Vote Coalition & STAR Voting - Advocating for voting methods that ensure every vote counts equally, eliminating wasted votes and strategic voting. Link: https://www.equal.vote/starFuture is Now Coalition (FiNC) - A grassroots movement working to restore democracy through transparency, accountability, and innovative technology while empowering citizens and transforming American political discourse. Link: https://futureis.org/ POLITICAL ENGAGEMENTIndependent Center - Resources for independent political thinking and civic engagement. Link: https://www.independentcenter.org/ GET DAILY NEWSText 844-406-INFO (844-406-4636) with code "purple" to receive quick, unbiased, factual news delivered to your phone every morning via Informed (https://informed.now) ALL LINKShttps://linktr.ee/purplepoliticalbreakdownThe Purple Political Breakdown is committed to fostering productive political dialogue that transcends partisan divides. We believe in the power of conversation, balanced information, and democratic participation to build a stronger society. Our mission: "Political solutions without political bias."Subscribe, rate, and share if you believe in purple politics - where we find common ground in the middle! Also if you want to be apart of the community and the conversation make sure to Join the Discord: https://discord.gg/ptPAsZtHC9
The ongoing conflict in the Middle East continues to create both challenges and opportunities. On In The Market with Janet Parshall this week we spoke with dedicated evangelist to the people of Iran who shared with us the difficulty that people are living through as the regime in power continues to exert control amidst water and electricity shortages. He told us despite the hardships more young people are turning away from Islam and discovering the life-giving hope of Christ and the gospel. Then we looked at the confusing actions of the FDA on abortion pills. A highly respected doctor who is on the front lines of the fight for the preborn explains why there are no protections for women who are encouraged to take the drugs, what these pills actually to the mother and baby and why it is important to tell women that there are other options and protections for them and their child. What can cause you to lose the joy and intimacy of your spiritual relationship with God? Our guest said that there are lies that many believers fall prey to that do that sort of damage to the believers walk. He explained those lies and gave us some clear biblical guidance of how to replace those lies with solid biblical truth. Sometimes the road of the Christian life seems to be full of potholes and speed bumps, but those difficulties are no surprise to a sovereign God who uses these obstacles to grow and mature His children in their faith. Our guest explained how living out your faith is the only way to navigate these challenges. We turned to one our favorite guests, a highly respected bible teacher and author to help us understand a vital part of the Christian life that many do not really understand or know how to implement in their lives, worship. He took us back to scripture to show us the necessity of worship and how it can transform and deepen your walk with the Lord. The end of the week is here, and we invite you to join our favorite husband and wife duo as they instruct us on how to use the Word to measure the confusing and misleading ideas that populate the marketplace of ideas.Become a Parshall Partner: http://moodyradio.org/donateto/inthemarket/partnersSee omnystudio.com/listener for privacy information.
A longstanding measurement of success for any President is the state of the economy. President Trump is no exception. A recent survey from the Associated Press and the NORC Center for Public Affairs Research finds that only one in three adults approve of President Trump's handling of the economy. FOX Business's White House correspondent Edward Lawrence joins the Rundown to discuss the Trump administration's handling of the issue of affordability for Americans. Later, Dr. Dorothy Fink, Deputy Assistant Secretary for Health & Women's Health at the Department of Health and Human Services, joins to discuss what led to the FDA's decision to remove its longstanding boxed warning from hormone-based menopause drugs. Learn more about your ad choices. Visit podcastchoices.com/adchoices
On this episode of Vitality Radio, Jared dives deep into one of the most fascinating frontiers in functional nutrition—brain energy. He unpacks how ATP fuels your mind, why BDNF acts like “fertilizer for neurons,” and how lifestyle stressors, toxins, and poor sleep can dim your mental lightbulb. From there, he explores the natural tools that can reignite focus, memory, and long-term cognitive vitality. You'll hear how powerhouse nutrients can support mitochondrial performance, boost brain-derived neurotrophic factor, and promote sharper thinking—without the crash of caffeine or pharmaceuticals. Jared wraps up with three practical, results-driven protocols: one for focus and ADHD support, one for immediate memory and cognition, and one for long-term prevention of cognitive decline. Each stack can be customized to fit your individual goals so you can think clearer, focus longer, and age smarter—naturally.Brain Boosting Protocol CollectionShop the collection! Bundle and save - no code needed, just add to your cart to get:Buy 2 at 10% offBuy 3-4 at 15% offBuy 5+ at 25% offAdditional Information:Brain Boosting Protocol Blog Post#335: The Latest Research on Preventing and Reversing Dementia and Alzheimer's with Dr. Dale Bredesen#570: Liquid Yoga & Mind Fuel: Harnessing Mushrooms and Herbs for Focus and Calm#511: Unraveling NAD+ and NMN for Longevity and Anti-AgingVisit the podcast website here: VitalityRadio.comYou can follow @vitalitynutritionbountiful and @vitalityradio on Instagram, or Vitality Radio and Vitality Nutrition on Facebook. Join us also in the Vitality Radio Podcast Listener Community on Facebook. Shop the products that Jared mentions at vitalitynutrition.com. Let us know your thoughts about this episode using the hashtag #vitalityradio and please rate and review us on Apple Podcasts. Thank you!Just a reminder that this podcast is for educational purposes only. The FDA has not evaluated the podcast. The information is not intended to diagnose, treat, cure, or prevent any disease. The advice given is not intended to replace the advice of your medical professional.
In the latest episode, Holly, Amy, and Kristen engage with Dr. Ben Schwartz about the complexities of hormonal changes, particularly during menopause. With the recent removal of misleading FDA warnings on hormone replacement therapy, this episode is timely and informative for women seeking clarity and support during this transformative phase of life. What can you do to help you feel like yourself again? And what about the changes men experience in the season Dr. Ben calls "manopause"? What about their changes and what they need? We talk about it! Join us for the conversation.
A longstanding measurement of success for any President is the state of the economy. President Trump is no exception. A recent survey from the Associated Press and the NORC Center for Public Affairs Research finds that only one in three adults approve of President Trump's handling of the economy. FOX Business's White House correspondent Edward Lawrence joins the Rundown to discuss the Trump administration's handling of the issue of affordability for Americans. Later, Dr. Dorothy Fink, Deputy Assistant Secretary for Health & Women's Health at the Department of Health and Human Services, joins to discuss what led to the FDA's decision to remove its longstanding boxed warning from hormone-based menopause drugs. Learn more about your ad choices. Visit podcastchoices.com/adchoices
A longstanding measurement of success for any President is the state of the economy. President Trump is no exception. A recent survey from the Associated Press and the NORC Center for Public Affairs Research finds that only one in three adults approve of President Trump's handling of the economy. FOX Business's White House correspondent Edward Lawrence joins the Rundown to discuss the Trump administration's handling of the issue of affordability for Americans. Later, Dr. Dorothy Fink, Deputy Assistant Secretary for Health & Women's Health at the Department of Health and Human Services, joins to discuss what led to the FDA's decision to remove its longstanding boxed warning from hormone-based menopause drugs. Learn more about your ad choices. Visit podcastchoices.com/adchoices
This episode covers: • Cocoa Extract Cuts Heart Deaths A massive COSMOS trial found that older adults taking high flavanol cocoa extract daily saw a 27 percent reduction in cardiovascular deaths along with drops in inflammation markers like HSCRP. Women showed unique anti inflammatory cytokine shifts, pointing to a broader longevity effect. Dave explains why cocoa extract is becoming a foundational nutrient for vascular health rather than a dessert ingredient. Source: https://www.sciencedaily.com/releases/2025/09/250926135957.htm • AI Stethoscope for Home Diagnostics Lapsi Health's Keikku 2.0 just became the first FDA cleared AI powered digital stethoscope for both clinicians and home users. It records heart and lung sounds, analyzes them instantly, and flags early warning signs before symptoms appear. Dave breaks down why tools like this move you from reactive to predictive medicine and why they belong in every quantified self toolkit. Source: https://www.prnewswire.com/news-releases/lapsi-health-unveils-keikku-2-0-worlds-first-fda-cleared-digital-stethoscope-with-integrated-ai-scribe-302585083.html?utm_source=chatgpt.com • Beef Organ Supplements Surge Beef organ supplements have exploded more than 8,000 percent this year, driven largely by women reporting improvements in energy, hormones, mood, and skin. Liver, kidney, and heart deliver vitamin A, heme iron, B12, copper, and choline that modern diets often lack. Dave covers sourcing concerns, purity standards, and why this shift reflects a move from fear based nutrition to evolutionary nutrition. Source: https://www.verywellhealth.com/beef-organ-supplement-11710185?utm_source=chatgpt.com • Spirulina for Collagen and DNA Protection New research highlights spirulina's ability to support collagen production, reduce oxidative stress, protect DNA, and improve glucose and lipid balance. It is becoming a staple of eco focused anti aging routines and is driving the viral green stacking trend with chlorella and chlorophyll. Dave explains why spirulina functions as a clean daily defense against oxidative stress. Source: https://www.news-medical.net/news/20250707/Is-Spirulina-the-Next-Anti-Aging-Superfood.aspx • Health Data Privacy Reform A new Senate bill aims to extend HIPAA level protections to wearables, genomic tools, glucose monitors, and wellness apps. The goal is to give users control over who sees their biometrics, how they are stored, and whether they can be sold. Dave outlines why this matters for anyone using Oura, Whoop, CGMs, or genetic testing and why your biology should belong to you and not the cloud. Source: https://natlawreview.com/article/federal-healthcare-update-november-7-2025 All source links provided for easy reference to the original reporting and research above. This is essential listening for fans of biohacking, hacking human performance, functional medicine, and longevity who want actionable tools from Host Dave Asprey and a guest who embodies what it means to age with energy, clarity, and vitality. Dave Asprey is a four-time New York Times bestselling author, founder of Bulletproof Coffee, and the father of biohacking. With over 1,000 interviews and 1 million monthly listeners, The Human Upgrade brings you the knowledge to take control of your biology, extend your longevity, and optimize every system in your body and mind. Each episode delivers cutting-edge insights in health, performance, neuroscience, supplements, nutrition, biohacking, emotional intelligence, and conscious living. New episodes are released every Tuesday, Thursday, Friday (audio-only), and Sunday (BONUS). Dave asks the questions no one else will and gives you real tools to become stronger, smarter, and more resilient. Keywords: cocoa extract, flavanols, heart health, nitric oxide pathways, COSMOS trial, AI stethoscope, digital diagnostics, Keikku device, predictive health tech, beef organ supplements, women's hormonal health, nutrient dense foods, ancestral nutrition, spirulina benefits, collagen support, oxidative stress defense, green stacking, chlorella pairing, DNA protection, wearable privacy laws, HIPAA reform, biometric data rights, longevity news, biohacking updates Thank you to our sponsors! Essentia | Go to https://myessentia.com/dave and use code DAVE for $100 off The Dave Asprey Upgrade. ECHO Water | Go to http://echowater.com/dave and use code DAVE10 for 10% off your ECHO Flask. Resources: • Subscribe to my weekly newsletter: https://substack.daveasprey.com/welcome • Danger Coffee: https://dangercoffee.com/discount/dave15 • My Daily Supplements: SuppGrade Labs (15% Off) • Favorite Blue Light Blocking Glasses: TrueDark (15% Off) • Dave Asprey's BEYOND Conference: https://beyondconference.com • Dave Asprey's New Book – Heavily Meditated: https://daveasprey.com/heavily-meditated • Upgrade Collective: https://www.ourupgradecollective.com • Upgrade Labs: https://upgradelabs.com • 40 Years of Zen: https://40yearsofzen.com Timestamps: 0:00 – Intro 0:19 – Cocoa Extract & Heart Health 1:52 – AI Digital Stethoscope 3:01 – Beef Organ Supplements 4:24 – Spirulina for Longevity 5:42 – Substack Announcement 6:53 – Health Data Privacy Reform 8:23 – Weekly Upgrade Protocol 9:46 – Outro See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
A grisly discovery thrusts the heroes deeper into the Gloaming, where the forest awakens and the shadows grow hungry. Watch the video here: https://youtu.be/gO3EleVdT4g Enter the Shadowdark at your gaming table by visiting https://www.thearcanelibrary.com/?utm_source=glasscannon This episode was sponsored by Foundry VTT and Norse Foundry. See why tabletop gamers everywhere have made the switch to Foundry Virtual Tabletop at https://foundryvtt.com/gcp For all your random number-generating needs, visit Norse Foundry at https://norsefoundry.com For simple, online access to personalized and affordable care for hair loss, visit https://hims.com/GCN (Individual results may vary. Based on studies of topical and oral minoxidil and finasteride. Featured products include compounded drug products, which the FDA does not approve or verify for safety, effectiveness, or quality. Prescription required. See website for full details, restrictions, and important safety information.) Executive Producer and Gamemaster: Troy Lavallee Cast: Sydney Amanuel, Matthew Capodicasa, Skid Maher and Joe O'Brien Cinematographer: Matt Brodie Producer and Editor: Francis Mrema Audio Engineer and Graphics: CJ Paschall Production Coordinator: Michael Mooridian Art Direction: Josh Fisher Intro Song: "In the Shadowdark" by Jason Charles Miller Performed by: Jason Charles Miller with Sydney Amanuel Access exclusive podcasts, ad-free episodes, and so much more with a 30-day free trial using code "GCN30" at http://www.jointhenaish.com For more podcasts and livestreams or to catch the next stop on the tour, visit https://hubs.li/Q03cmWCk0 Watch new episodes when they premiere every Thursday at 8PM ET on youtube.com/theglasscannon. Learn more about your ad choices. Visit megaphone.fm/adchoices
It's Nurse Practitioners Week, and today, we have a special episode to highlight a historic moment in time. On November 11, the FDA changed the labeling on hormone replacement therapy. Join me for a short, focused episode where I read a recently published JAMA article detailing those changes, to keep you up to date on this significant development. IN THIS EPISODE, YOU WILL LEARN: How recent FDA updates are changing menopausal hormone therapy The history of estrogen's role in heart and bone health How past research sparked fear around hormone therapy What the new labeling means for patients and prescribers How individualized treatment is reshaping dosage and timing decisions. Updated FDA labeling now distinguishes between systemic and topical therapies Key considerations for menopause-related urinary and genital health How these updates will potentially impact women's long-term health Connect with Cynthia Thurlow Follow on X, Instagram & LinkedIn Check out Cynthia's website Submit your questions to support@cynthiathurlow.com
Muscle-bound bodybuilders may line up for testosterone replacement therapy – and increasingly, so do menopausal women. Susan Dominus, staff writer at The New York Times Magazine, joins host Krys Boyd to discuss why middle-aged women are raving about its benefits — despite possible side effects — and why the FDA hasn't approved any use of the hormone for women. Her article is “‘I'm on Fire': Testosterone Is Giving Women Back Their Sex Drive — and Then Some.” Learn about your ad choices: dovetail.prx.org/ad-choices
In this special episode, Ali is bringing you the unforgettable keynote from style expert, author, and powerhouse storyteller Lilliana Vasquez at Fertility Rally Live. Lilliana opens up about her deeply personal journey to motherhood, including the emotional twists, cultural layers, and unexpected turns her family-building path took. With her signature candor, humor, and heart, she shares what it was like to navigate infertility while living in the public eye—and how it ultimately reshaped her identity, her career, and her purpose. She talks about resilience, community, representation, and the importance of seeing yourself reflected in the stories around you. Lilliana also dives into the powerful role that vulnerability plays in healing, and offers encouragement for anyone who's still in the messy middle of their journey.EPISODE SPONSORS: BEAUTIFUL BIRD AND WORK OF ARTAli's Children's Book Series about IVF, IUI and Family Building Through Assisted Reproductive Technology https://www.infertileafgroup.com/booksThe latest book in the Work of ART series, “Beautiful Bird” tells the story of three parents, one incredible boy and a family built with love—and a little bit of science.Pre-orders are available now! The first 150 copies will be Personalized, Signed and Numbered! Don't miss out on this limited edition! Tap the link in bio and stories to order your copy today.When Helen decides to have a baby on her own, she welcomes Jack Bird into the world through IUI with the help of her friend, Aaron. But when Jack is born and needs extra care in the NICU, Aaron and his partner, Blake, fall in love with Jack, too. Together, the three join forces to raise Jack, proving that family isn't about how you start—it's about how you grow.Order yours now at https://www.infertileafgroup.com/booksFERTILITY RALLYIG: @fertilityrallywww.fertilityrally.comNo one should go through infertility alone. Join the Worst Club with the Best Members at fertilityrally.com. We offer 5 to 6 support groups per week, three private Facebook groups, tons of curated IRL and virtual events, and an entire community of more than 500 women available to support you, no matter where you are in your journey.Join today at link in bio on IG @fertilityrally or at www.fertilityrally.com/membershipPHERDALIG: pherdal_sciencePherDal is the world's first and only FDA-cleared, sterile, at-home insemination kit designed to help people build their families in the comfort of home. Created by parents who've been there, PherDal is safe, simple, and affordable—putting more options in your hands as you grow your family. Explore at PherDal.com.Support this podcast at — https://redcircle.com/infertile-af-infertility-and-modern-family-building-through-art/donationsAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy
It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: It's World Diabetes Day and we have a LOT of news to get to! Daily oral insulin tested to prevent T1D, mothers and sons and a T1D link, stem cell updates, Tandem Android news, Omnipod's workplace campaign and more! Find out how to submit your Community Commercial Find out more about Moms' Night Out Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. It's world diabetes day! It is marked every year on 14 November, the birthday of Sir Frederick Banting, who co-discovered insulin along with Charles Best in 1922. WDD was created in 1991 by International Diabetes Federation (IDF) and the World Health Organization and became an official United Nations Day in 2006 with the passage of United Nations Resolution 61/225. There will be a ton of stuff in your feeds today and that's great! I'm going to keep this to a pretty normal in the news episode.. although I do have my own World Diabetes Day announcement – I want YOUR community commercials. You could have an ad for your event or your blog or your project right here! There's a post on the website explaining it all and I'll come back at the end of the episode and tell you more. XX The Primary Oral Insulin Trial (POInT) is the first large-scale clinical trial to test whether giving at-risk children daily oral insulin could prevent or delay type 1 diabetes (T1D). Conducted by researchers from Helmholtz Munich and the Technical University of Munich across five European countries, the study enrolled more than 1,000 children with a genetic risk for T1D. Results published in The Lancet show that while oral insulin did not prevent the development of islet autoantibodies—an early sign of diabetes—it was safe and well tolerated. Importantly, researchers found that some children who received oral insulin developed diabetes more slowly than those given a placebo, suggesting potential protective effects in certain genetic subgroups. Further analysis revealed that the response to treatment depended on the child's insulin gene variant. Children with genetic versions that raise diabetes risk appeared to benefit, showing delayed onset of the disease, while those without the risk variant did not. These findings point toward a future of personalized prevention, where genetic screening could help identify which children might benefit most from oral insulin. Researchers will continue following the participants until age 12 to assess long-term effects. The study marks a major milestone in decades of diabetes prevention research, highlighting both the promise and complexity of developing tailored, early interventions against type 1 diabetes. XX Joint US-Chinese research looking at generating new beta cells from stomach cells. Upon turning on the "genetic switch," the human stomach cells were converted to insulin-secreting cells within the mice and resembled pancreatic beta cells with respect to gene and protein expression. Encouragingly, when those experiments were done with diabetic mice, insulin secreted from the transformed human cells helped control blood sugar levels and ameliorated diabetes. The scientists hope that a similar approach can be taken to convert cells from a patient's own stomach into insulin-secreting cells directly within the body. Importantly, additional studies are needed to address if this approach is safe and effective to be used in patients. https://www.technologynetworks.com/cell-science/news/human-stomach-cells-tweaked-to-make-insulin-406694 XX A new study in Nature Metabolism may help explain why children born to mothers with type 1 diabetes are less likely to develop the disease early in life compared to those whose fathers or siblings have it. Researchers looked at nearly 2,000 mothers and their children and found that kids whose moms have type 1 diabetes show changes in their DNA that may actually help protect them. These aren't genetic mutations, but epigenetic changes — chemical tags that turn certain genes on or off. The study found these changes in genes tied to the immune system and type 1 diabetes risk, suggesting that a mother's condition during pregnancy can shape her child's immune response in a protective way. Scientists identified more than 500 areas of DNA where these changes occurred, many in regions that control how the body's immune system works. Most of the changes appeared to calm down the kind of overactive immune response that leads to type 1 diabetes. Researchers even created a "methylation score" to help measure this protective effect. They say the next step is to confirm these results in more diverse groups and figure out exactly how these DNA changes help prevent early diabetes. https://www.news-medical.net/news/20251110/Maternal-type-1-diabetes-may-protect-children-from-developing-the-disease.aspx XX A new study from Karolinska Institutet and Stockholm University reveals that sons born to mothers with type 1 diabetes may develop early vascular dysfunction—independently of metabolic health. The finding may help shape future strategies to prevent cardiovascular disease early in life. Children of women with type 1 diabetes are known to be at increased risk of developing cardiovascular diseases. This new study, published in Cell Reports Medicine, is the first to show that the risk is linked to early dysfunction in blood vessel cells in sons, even before any metabolic issues arise. The team is now investigating the long-term effects of maternal diabetes, with a particular focus on why sons seem to be affected earlier than daughters. https://medicalxpress.com/news/2025-11-sons-mothers-diabetes-early-vascular.html XX A new study presented at Kidney Week 2025 has shown that the drug finn-uh-near-own a nonsteroidal mineralocorticoid-receptor antagonist, significantly reduced albuminuria—a key marker of kidney damage—in people with type 1 diabetes (T1D) and chronic kidney disease (CKD). This is the first major breakthrough for this population in more than 30 years. Researchers found that patients taking finerenone saw a 25% average reduction in albuminuria compared to placebo, an improvement that suggests a lower long-term risk for dialysis or kidney transplant. The phase 3 FINE-ONE trial involved 242 adults with T1D and CKD, and results showed benefits as early as three months. The drug was generally well tolerated, with side effects similar to those seen in patients with type 2 diabetes, though mild hyperkalemia (high potassium levels) was slightly more common. Experts say the findings could change the way doctors treat kidney complications in type 1 diabetes, an area that hasn't seen new therapies since the early 1990s. Currently, treatment options rely on blood pressure and blood sugar management, along with renin-angiotensin system (RAS) inhibitors. Finerenone, which is already approved for type 2 diabetes-related CKD, targets overactivation of a receptor that drives kidney damage. Based on these results, Bayer plans to seek FDA approval in 2026 for use in people with T1D and CKD. Researchers and clinicians alike are calling the study "groundbreaking," noting that it opens the door to future research on how finerenone might not just slow kidney decline—but possibly prevent it altogether. https://www.medscape.com/viewarticle/finerenone-offers-hope-kidney-disease-type-1-diabetes-2025a1000uzi?form=login XX This week, Tandem Diabetes Care (Nasdaq:TNDM) announced a major milestone for its Mobi miniature durable insulin pump system. San Diego-based Tandem revealed that it received FDA approval for the Android version of its Mobi mobile app. Clearance brings Mobi — which the company describes as the world's smallest, durable automated insulin delivery system — to more users. The pump, which pairs with Tandem's Control-IQ+ algorithm, previously worked with iOS software. Tandem — one of the largest diabetes tech companies in the world — expects to begin a limited rollout next month, followed by full commercial availability in early 2026. This marks the latest milestone for the company, which continues to expand its offerings and widen its reach within the diabetes patient population. We had a great interview with Tandem on our previous episode, but as I said at the time, it was coming before their earnings call. So here's an update: The company plans to submit the tubeless mobi to the fda before the end of this year.. possible approval and shipping date is hoped for by middle of 2026. Trials for their fully closed loop next-generation algorithm which we tlkaed abou ton the show should be launched in 2026 The Sigi patch pump will be developed and launched as a next-generation version of the Mobi Great job by Dr. David ? Ahn – he posted on IG after getting a message from tandem CEO John Sheridan? 1. First, the Tandem X3 *is* still absolutely in development, contrary to my speculation In yesterday's video. As many of you appropriately pointed out, there is definitely a market for a 300 unit pump, a pump with a screen, and a pump that does not require smartphone control. So from our brief chat, the sense I got that is that the X3 would be more of a refresh of the X2 with newer components, such as a USB-C connector and better memory, rather than a total redesign from the ground up. In terms of timing, all I could get was that it was "not too far distant in the future," which could mean anything I guess, but at least it's still on the way! 2. Next up, he also reassured me that they are working closely with Dexcom to support the G7 15 Day sensor within the next few months. I suspected as much, but it's always good to hear confirmation. 3. Lastly, he did confirm that Tandem is far along in developing a Caregiver/Follow app to allow the remote viewing of glucose and insulin data from a Tandem pump. He explained that it will be based on Sugarmate, the popular diabetes data dashboard app that Tandem acquired back in Jun 2020. While I don't know if every feature will make it into the Tandem caregiver app, Sugarmate is well-liked for its highly customizable dashboard and highly configurable alerts. Sugarmate even has the option to send a text message or phone call for urgent lows. Regardless, a true follow/Caregiver app will be welcomed with open arms by all caregivers and Tandem users who use Libre 3 Plus. https://time.com/7318020/worlds-top-healthtech-companies-2025/ XX Senseonics submits Eversense 365 – their year long implantable CGM for a CE mark, European Approval and expect to launch there soon. Eversense will be integrated with the sequel twist pump – again I'm hearing soon but no timeline. Intersting to note that one year inseration was approved in the US just about a year ago, so the first patients will be having their CGMs changed out – for the first time – pretty soon. https://www.drugdeliverybusiness.com/senseonics-q2-2025-sales-beat-ce-mark/ XX A confusing study out of Rutgers - these researcher say metformin reduces some of the key benefits normally gained from regular physical activity. These include improvements in blood vessel health, physical fitness, and the body's ability to regulate blood sugar. Since 2006, doctors have typically encouraged patients with elevated blood sugar levels to combine metformin with exercise, expecting that the two proven treatments would produce stronger results together. However, the new research suggests this may not be the case. In this study, Exercise alone improved vascular insulin sensitivity, meaning blood vessels responded better to insulin and allowed more blood flow to muscles. This matters because insulin's ability to open blood vessels helps shuttle glucose out of the bloodstream and into tissues, lowering blood sugar after meals. But when metformin was added, the improvements shrank. The drug also diminished gains in aerobic fitness and reduced the positive effects on inflammation and fasting glucose. The findings don't mean people should stop taking metformin or exercising, Malin said. Instead, it raises urgent questions for doctors about how the two treatments can be combined and the need for close monitoring. Malin hopes future research will uncover strategies that preserve the benefits of both. https://scitechdaily.com/popular-diabetes-drug-metformin-may-cancel-out-exercise-benefits-study-warns/ XX XX https://www.medtechdive.com/news/Revvity-Sanofi-diabetes-test-Kihealth-seed-round/802133/ XX Dexcom recalled an Android app for its G6 glucose sensor due to a software problem that could cause the app to terminate unexpectedly. The issue could cause users to miss alarms, alerts or notifications related to estimated glucose values, according to a Food and Drug Administration database entry posted Oct. 30. The glucose sensor and the app are still available, but Dexcom required users to update the app to a new version. Dexcom began the recall on Aug. 28. The FDA designated the event as a Class 1 recall, the most serious kind. Dexcom sent a notification to customers in September about the software bug, which applies to version 1.15 of the G6 Android app. To use the app, customers must update it to a new version, according to the entry. https://www.medtechdive.com/news/dexcom-recall-g6-cgm-app/804630/ XX https://www.medscape.com/viewarticle/automated-insulin-delivery-boosts-glycemic-control-youth-2025a1000ub3 XX Tidepool partners with smart ring maker OURA.. press release says: to support a groundbreaking dataset intended to be broadly available for diabetes research, with participation limited to individuals who opt in through Tidepool. Tidepool will pair biometric data from Oura Ring – sleep, activity, heart rate, temperature trends, and menstrual cycles – with diabetes device data, including continuous glucose monitors (CGMs) and insulin pumps. The result will provide researchers with an unprecedented dataset to accelerate the development of new clinical guidelines, next-generation diabetes technology, and personalized care models. Recruitment is expected to launch in early 2026 through an IRB-approved study. By opting in to this study, participants consent to sharing their data with Tidepool's Big Data Donation Project, where data is de-identified and, with participant consent, shared with academics, researchers, and industry innovators to accelerate diabetes research. https://aijourn.com/tidepool-collaborates-with-oura-to-advance-inclusive-diabetes-research-through-wearables/ XX Eli Lilly launches two new clinical trials for baricitinib. These phase 3 trials will investigate whether the drug can delay T1D onset or progression and will open for recruitment soon. Baricitinib has the potential to extend the "honeymoon period" of T1D, meaning that it could preserve remaining insulin-producing beta cells earlier in disease progression. More beta cells mean better blood sugar management—and potentially reduced long-term complications. JAK inhibitors, including baricitinib, are already FDA-approved for other autoimmune diseases, such as rheumatoid arthritis, alopecia, and more. JAK signaling pathways are associated with overactive immune responses, so blocking this pathway may turn down the immune response. The phase 2 Breakthrough T1D-funded BANDIT study was key in showing that this drug is safe and effective in T1D. Importantly, baricitinib is a once-daily oral pill—meaning its use is simple and easy. https://www.breakthrought1d.org/news-and-updates/two-new-trials-baricitinib-to-delay-t1d/ XX Insulet is taking diabetes awareness into the workplace. Having found 79% of people with diabetes have faced bias or misunderstanding at work, the medtech giant is rolling out a range of resources intended to trigger changes in how workplaces approach the condition. Lots going on for Diabetes Awareness month.. some notables.. Insulet's "The Day Diabetes Showed up to Work" campaign. based on a survey of almost 10,000 people 79% of people with diabetes have faced bias or misunderstanding at work,. Almost 90% of people with diabetes surveyed reported experiencing barriers at work due to their condition, and more than 40% of people with diabetes and caregivers said they have workplace-related anxiety tied to the metabolic disease. Around one-quarter of respondents reported fears that diabetes could limit opportunities or lead to workplace discrimination and judgment, and a similar proportion of people said they conceal their condition. https://www.fiercepharma.com/marketing/widespread-workplace-challenges-people-diabetes-spark-insulet-campaign XX New directive issued by the Trump administration could mean people seeking visas to live in the U.S. might be rejected if they have certain medical conditions, including diabetes or obesity. The guidance, issued in a cable the State Department sent to embassy and consular officials and examined by KFF Health News, directs visa officers to deem applicants ineligible to enter the U.S. for several new reasons, including age or the likelihood they might rely on public benefits. The guidance says that such people could become a "public charge" — a potential drain on U.S. resources — because of their health issues or age. The cable's language appears at odds with the Foreign Affairs Manual, the State Department's own handbook, which says that visa officers cannot reject an application based on "what if" scenarios, Wheeler said. The guidance directs visa officers to develop "their own thoughts about what could lead to some sort of medical emergency or sort of medical costs in the future," he said. "That's troubling because they're not medically trained, they have no experience in this area, and they shouldn't be making projections based on their own personal knowledge or bias." Immigrants already undergo a medical exam by a physician who's been approved by a U.S. embassy. https://www.npr.org/2025/11/12/nx-s1-5606348/immigrants-visas-health-conditions-trump-guidance XX SAN DIEGO---Nov. 14, 2025—DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today unveiled 16 new diabetes advocates to represent people living with diabetes globally as part of Dexcom's World Diabetes Day campaign. The advocates – ranging from ages six to 68, spanning various types of diabetes, and hailing from four continents and five countries – were selected from 1,000 open call submissions based on their experiences advocating for people with diabetes in their communities. While each person's experience with diabetes is unique, they share a common passion for advocacy – and use of Dexcom's glucose biosensing technology. "Through advocacy, I strive to show others, especially children and newly diagnosed patients, that diabetes is not a limitation but an opportunity to grow stronger, inspire resilience and pursue ambitious goals," said Maria Alejandra Jove Valerio, one of Dexcom's new advocates. "What began as a diagnosis at age seven has grown into a lifelong mission to uplift others." This effort represents the first time Dexcom has sourced voices from the broader diabetes community specifically for its World Diabetes Day campaign, reinforcing Dexcom's history of and commitment to giving real people with diabetes a platform to share their story on a global stage. Through engaging, editorial-style portraits and deeply personal stories, the campaign highlights each advocate's personal experience with diabetes, what misconceptions about diabetes they'd like to dispel and how they want to inspire others with diabetes to discover what they're made of. To prepare for the spotlight, the group of advocates met in Los Angeles for a World Diabetes Day photoshoot which included a surprise visit from Grammy-nominated artist, actor, producer and Dexcom Warrior Lance Bass and author, producer, actress and Stelo*Ambassador Retta. This visit offered the advocates an opportunity to exchange stories and personal perspectives on the meaning of diabetes advocacy and how they live it each day. Behind the lens at the shoot was another member of the diabetes community—photographer Tommy Lundberg who lives with Type 1 diabetes. "Directing this photoshoot was nothing short of inspiring. Each of these advocates has a unique an XX On what would have been the 100th birthday of its visionary founder Alfred E. Mann, MannKind Corporation (Nasdaq: MNKD), in partnership with Alfred E. Mann Charities and The Diabetes Link, announced the launch of the Centennial Al Mann Scholarship. The new program will distribute $100,000 in scholarship funds to support at least 10 young adult students living with diabetes as they pursue higher education in life sciences. Launched in Diabetes Awareness Month, the scholarship program honors Alfred E. Mann's enduring legacy of innovation, philanthropy, and his lifelong commitment to improving the quality of human life through medical advancement. Deeply passionate about giving back, Mr. Mann believed that his success should continue to serve humanity long after his passing, a belief that lives on through this initiative. Each scholarship recipient will be awarded up to $10,000, distributed in annual installments of $2,500 throughout the course of their studies. Depending on the length of their degree program, recipients may receive between two and four installments (up to the full $10,000 per student). The first awards will be made for the 2026 academic year. "Al Mann dedicated his life to helping people with serious medical conditions live longer, healthier lives. This scholarship is a reflection of that spirit," said Michael Castagna, PharmD, Chief Executive Officer of MannKind Corporation. "By supporting students living with diabetes who are pursuing careers in the life sciences and adjacent fields, we're honoring Al's legacy and investing in the future of innovation and care. This program is about giving back to the community we serve and empowering the next generation to carry forward Al's mission of making a meaningful difference in people's lives." Alfred E. Mann Charities and MannKind will partner with The Diabetes Link to launch the program to serve young adults (aged 18-22) living with either type 1 or type 2 diabetes with their higher education goals. Those eligible will include incoming freshmen and current students pursuing 2- or 4-year degrees. The application window will open in early 2026, and for those interested in receiving notifications, an early interest form is available. More information about the scholarship will be shared on thediabeteslink.org. "We're honored to partner with MannKind to expand access to higher education for young adults with diabetes," said Manuel Hernández, Chief Executive Officer of The Diabetes Link. "At a time when the cost of college continues to rise, this scholarship helps ease the financial burden and carries forward the spirit of Al Mann, whose vision and legacy continue to inspire us." Mr. Mann was MannKind's Chairman of the Board from 2001 until his passing in February 2016 and served as Chief Executive Officer from November 2003 until January 2015. Driven by a desire to improve lives and fill unmet medical needs, for more than six decades he founded 17 companies and developed breakthrough medical devices, including insulin pumps, cochlear implants, cardiac pacemakers and retinal prostheses. In 1997, Mr. Mann saw the potential of a dry powder insulin formulation to change the way diabetes is treated and invested nearly $1 billion to help bring Afrezza® (insulin human) Inhalation Powder to market. About MannKind MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, we develop and commercialize treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. With deep expertise in drug-device combinations, MannKind aims to deliver therapies designed to fit seamlessly into daily life. Learn more at mannkindcorp.com. About Alfred E. Mann Charities, Inc. Alfred E. Mann Charities, Inc. became active in 2016, following the passing of the organization's benefactor, Alfred E. Mann. Throughout his life, Al was passionate about philanthropy and was dedicated to prolonging and improving the quality of human lives through innovation in the fields of healthcare and the use of medical devices. It was important to Al that his success and assets continue to better human lives even after his own passing. Alfred E. Mann Charities, Inc. (formerly known as Alfred E. Mann Family Foundation) has similarly placed its primary focus on healthcare and medical innovation, as our organization believes this is where we can have the greatest impact on humanity and human health throughout the world. Alfred E. Mann Charities, Inc. is also dedicated to promoting arts, culture, education, and community development across Los Angeles and throughout the world in order to best serve people and this planet. Learn more at aemanncharities.org. About The Diabetes Link The Diabetes Link is the only national nonprofit organization dedicated to empowering young adults living with diabetes. Founded by and for young adults, The Link serves this community through peer support, leadership opportunities, and practical, evidence-based resources designed for real life. Its network of campus and community chapters, active online community, and robust Resource Hub help young adults navigate the transitions of early adulthood while managing diabetes. The organization envisions a future where every young adult living with diabetes has
Send Zorba a message!ProPublica (an independent, non-profit news organization) recently reported on the FDA's handling of potential safety issues concerning generic drugs we get from overseas manufacturers. Some of their findings include:· For decades, the FDA has blacked out the names of generic drugs on inspection reports for foreign factories that were found to have safety and quality violations. · This has prevented patients, doctors, and pharmacists from knowing whether manufacturing failures have made medications ineffective or unsafe. You can find the ProPublica article here(Recorded Nov 10, 2025)Support the showProduction, edit, and music by Karl Christenson Send your question to Dr. Zorba (he loves to help!): Phone: 608-492-9292 (call anytime) Email: askdoctorzorba@gmail.com Web: www.doctorzorba.org Stay well!
Natasha is joined by Dr. Lisa Diamond and Dr. Scout on this episode of the Natasha Helfer Podcast. This is a powerful episode as, in Lisa's words: "Scout and I have witnessed the entire birth and now destruction of the field of queer and trans mental and physical health (Scout is 60, I'm 54), so we have lived through this whole weird arc of seeing lgbtq health become a legitimate profession, and now it's being threatened—it's both personally and professionally devastating for both of us to witness this happening. "It is astounding that at a time when we recently survived a global pandemic that left so many people feeling isolated in ways that has profoundly affected our mental and physical health… and at a time when we have very clear data on the risk of suicide and lessened wellbeing for the LGBTQI+ community due to societal discrimination… that the government is choosing to dismantle and destroy so many departments/entities meant to support the health, science and data collection of ALL Americans." Dr. Diamond and Dr. Scout have created a survey for anyone affected by the current administration. Please consider filling it out. "We launched the study with zero funding, it's driven by pure love and panic, and it's affecting EVERYONE who loves or works with queer or trans people, including family members, friends, social workers, physicians, school, teachers, therapist, educators, EVERYONE. All of us are going through something, and we are going through this at the same time that the federal government has CEASED all data collection on our health. So Scout and I figured "OK, you don't wanna do this? We're just gonna have to do it ourselves." Go here to fill out the survey: https://csbsutah.co1.qualtrics.com/jfe/form/SV_9WyKRPONJuL67Yy?fbclid=IwY2xjawOEdthleHRuA2FlbQIxMABicmlkETFoOW43aDJMdnNGb1kwSThZc3J0YwZhcHBfaWQQMjIyMDM5MTc4ODIwMDg5MgABHkWvMqhUx7OYFY_0kbvt2yVu911j1Ch5DAnsBloLDDgUw1CHSZ3BRNwBhq3A_aem_2e27bX8Xk_kP7utbPv482g Also, if you're an organization that would like to partner with this project reach out to: research@cancer-network.com From Natasha: I loved Lisa's reminder that we survive oppression and destruction through connection. This is a small thing we can do to make a difference and that in of itself is healing and empowering. Please take the 20-25 minutes to fill out this survey. And please forward it to anyone you know who is impacted. Scout, PhD (they/he) is the Executive Director of the National LGBTQI+ Cancer Network and the principal investigator of both the CDC-funded LGBTQI+ tobacco-related cancer disparity network and Out: The National Cancer Survey. They spend much of their time providing technical assistance for tobacco and cancer focusing agencies expanding their reach and engagement with LGBTQI+ populations. Scout has a long history in health policy analysis and a particular interest in ensuring research and surveillance activities include LGBTQI+ people. They have faculty appointments at Dartmouth Cancer Center and Boston University's school of public health. They are a member of FDA's Tobacco Products Scientific Advisory Committee, on the Advisory Panel for NIH's All of Us initiative, and a former member of NIH Council of Councils as well as former Co-Chair of the NIH Sexual and Gender Minority Research Office Work Group. Their work has won them recognition from the U.S. House of Representatives, two state governments, and many city governments. Scout is an openly nonbinary and trans father of three, an avid hiker, and is currently training for the aptly named Dopey Challenge races at Disney. Lisa M. Diamond, Ph.D., is a Distinguished Professor of Psychology and Gender Studies at the University of Utah and a past president of the International Academy for Sex Research. For nearly 30 years, she has studied gender and sexuality across the lifespan, with current work centered on social safety and its impact on the health and well-being of LGBTQ+ individuals. Dr. Diamond is internationally recognized for her pioneering research on sexual fluidity, including her award-winning book Sexual Fluidity (Harvard University Press). She co-edited the first APA Handbook of Sexuality and Psychology, is a fellow of two APA divisions, and has published over 150 scholarly works. Her research has been supported by major national foundations, and she has delivered more than 200 invited talks worldwide, including a TED Talk with over 700,000 views. — Join Natasha February 11-17th 2026 on a cruise leaving out of Tampa, Florida. You can grab a package and work with Natasha on the ship. Sign up before January 1st and you get the early bird special: Natasha packages: $750 per couple $675 per couple - early bird (before January 1st) Payment plans are available. For further questions, email Mimi at unleashedvacations@gmail.com. Book now to make sure you don't miss out! See you on board. — To help keep this podcast going, please consider donating at natashahelfer.com and share this episode. To watch the video of this podcast, you can subscribe to Natasha's channel on Youtube and follow her professional Facebook page at natashahelfer LCMFT, CST-S. You can find all her cool resources at natashahelfer.com. The information shared on this program is informational and should not be considered therapy. This podcast addresses many topics around mental health and sexuality and may not be suitable for minors. Some topics may elicit a trigger or emotional response so please care for yourself accordingly. The views, thoughts and opinions expressed by our guests are their own and do not necessarily reflect the views or feelings of Natasha Helfer or the Natasha Helfer Podcast. We provide a platform for open and diverse discussions, and it is important to recognize that different perspectives may be shared. We encourage our listeners to engage in critical thinking and form their own opinions. The intro and outro music for these episodes is by Otter Creek. Thank you for listening. And remember: Symmetry is now offering Ketamine services. To find out more, go to symcounseling.com/ketamine-services. There are also several upcoming workshops. Visit natashahelfer.com or symcounseling.com to find out more.
In this episode of Molecule to Market, your host Raman Sehgal discusses the pharmaceutical and biotechnology supply chain with Jean-François Brepson, Chief Executive Officer at PathoQuest. The conversation covers: Navigating 20 years of global leadership roles at Ipsen before moving from the corporate world into an investor-led entrepreneurial adventure The tough decision to refocus PathoQuest from diagnostics into a pure play CRO and pharma services business How a major strategic partnership transformed the company's trajectory and why Jean sees partnerships as a competitive weapon Riding the tailwind of the FDA's move away from animal testing and offering something game-changing in the CMC and GMP space The opportunities ahead for CROs and CDMOs in helping unlock the next wave of innovation Jean-François Brepson is a dedicated leader with deep experience in biotechnology and pharmaceuticals. Since becoming CEO of PathoQuest in 2015, he has built the company into a leading global CRO specializing in quality control of biological drugs using Next Generation Sequencing (NGS). Over his career, he has advanced innovative technologies and solutions that bridge scientific progress with real-world application. Prior to joining PathoQuest, Jean was Senior Vice President at Ipsen, where he led the global GI-Oncology and Endocrinology franchise. Molecule to Market is sponsored by Bora Pharma, Charles River, and Lead Candidate. Please subscribe, tell your industry colleagues, and help us celebrate the value of the global life science outsourcing space. We'd also appreciate a positive rating!
Send Zorba a message!ProPublica (an independent, non-profit news organization) recently reported on the FDA's handling of potential safety issues concerning generic drugs we get from overseas manufacturers. Some of their findings include:· For decades, the FDA has blacked out the names of generic drugs on inspection reports for foreign factories that were found to have safety and quality violations. · This has prevented patients, doctors, and pharmacists from knowing whether manufacturing failures have made medications ineffective or unsafe. You can find the ProPublica article here(Recorded Nov 10, 2025)Support the showProduction, edit, and music by Karl Christenson Send your question to Dr. Zorba (he loves to help!): Phone: 608-492-9292 (call anytime) Email: askdoctorzorba@gmail.com Web: www.doctorzorba.org Stay well!
When a man can secretly order abortion pills in his wife’s name and force them on his pregnant girlfriend, something is deeply broken in our culture. This week's episode of The Narrative breaks down a shocking Ohio case that exposes the growing dangers of unregulated abortion pill access and the cultural ideology enabling it. Aaron, David, and Mike unpack how current FDA rules allowed a man to order abortion drugs in his wife’s name and forcibly give them to his pregnant girlfriend. They also highlight the media’s stunning lack of coverage, the worldview driving that silence, and what must happen now to protect women from coercion and abuse. After their discussion, Evans and Ben Nwankwo of Ambassadors for Self Determination—native Nigerian brothers who now live in Ohio—join the conversation to expose the brutal reality of Christian persecution in Nigeria and an ongoing genocide claiming roughly 30 lives every day. The guys unpack the violence, the government’s complicity, and how US pressure and foreign-aid leverage could finally force change. Don't miss this episode, which pulls back the curtain on two stories the mainstream won’t touch and learn what must happen to protect women and save persecuted Christians. Take Action As Christians, we must act now! Our brothers and sisters in Nigeria are facing a daily threat most of the world refuses to acknowledge, and Congress needs to hear from believers who won’t look away. Take one minute today to contact your US Representative and Senators through our Action Center and urge them to back Senator Cruz’s legislation. Your voice can help push America to stand up, apply the pressure, and protect innocent Christians before more lives are lost. Also, the Trump Administration can restore protections for women and their children by reinstating the safeguards around the abortion pill. Use CCV’s Action Center to contact your members of Congress and federal leaders today, it takes just 60 seconds to demand real accountability and save lives.
In this episode, Brent is joined by endocrinologist and longtime FDA leader Dr. G. Alexander Fleming to break down one of the most consequential diseases of modern life: type 2 diabetes. Dr. Fleming explains the real difference between type 1 and type 2, why insulin resistance is the root problem, and how biomarkers like fasting glucose, A1C, and fasting insulin work together to reveal your true metabolic health. He also discusses the promises and pitfalls of blockbuster medications like metformin and semaglutide, the public-health failures that helped fuel today's metabolic crisis, and why strength training may be one of the most important longevity tools we have. Hope you enjoy.
Ask Me A Question For Next Week's Episode!Included in this week's episode: Personal story with the politicization of fitness and it's affects on my community today. Brief history of fitness and politics. Modern politics and fitness in the military and presidents. The socioeconomic and class division of fitness and politics. Pilates. Fitness in America today is highly individualized. Fitness in liberalism and conservatism inappropriately integrates morality, religion and political beliefs into fitness and food. The nuances of extremist political conclusions of food and fitness. Food as a human right around the world and in America. Political impacts on your fitness in government like the EPA, FDA, healthcare, federal standards and more. Final message: whatever your government is willing to do to the least of the society or those abroad, they will do to you. Full stop. The government will no hesitate to withhold food from it's civilians just like it does on the global setting. The beliefs and standards you hold for individualized fitness and food is where the government will stop. If you believe it's a personal issues, then your government will not help you. Ask more of the system you pay for. You are most similar to someone on SNAP than you are to a representative. We are all one moment away from needing a subsidy to help us live. Remember, most importantly, the government officials and law makers and the wealthiest of those in our country exist because of subsidy that YOU pay for. Demand more from your government. They are already used to providing it.
The Friday Five for November 14, 2025: iPhone Pocket Brings Back… Pockets. CMS Rural Health Transformation Program Government Shutdown Update Most-Favored Nation Drug Pricing CMS GENEROUS Model Get Connected:
Biochemist Lingyin Li survived breast cancer at just 30 and now works to harness the human immune system to fight cancers that have long evaded treatment. T cells, she says, are powerful cancer killers, but they can be oblivious. She and her lab colleagues have discovered a masking enzyme that squelches the immune system's “danger signals” and are now developing drugs to block that enzyme. She likens her work to an arms race between cancer and immunotherapy. “The cancers are not getting smarter, but we are,” Li tells host Russ Altman on this episode of Stanford Engineering's The Future of Everything podcast.Have a question for Russ? Send it our way in writing or via voice memo, and it might be featured on an upcoming episode. Please introduce yourself, let us know where you're listening from, and share your question. You can send questions to thefutureofeverything@stanford.edu.Episode Reference Links:Stanford Profile: Lingyin LiConnect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>> Twitter/X / Instagram / LinkedIn / FacebookChapters:(00:00:00) IntroductionRuss Altman introduces guest Lingyin Li, a professor of biochemistry at Stanford University.(00:03:38) Research MotivationLingyin explains how her breast cancer diagnosis inspired her research.(00:04:31) How T-Cells WorkT-cell mechanisms and why they struggle to reach solid tumors.(00:05:38) Immune System OverviewInnate and adaptive immunity and how mutations make cancer recognizable.(00:07:28) Awakening the Immune SystemEfforts to stimulate innate immune cells to detect and expose tumors.(00:10:54) The Cancer SignalDiscovery of cancer-derived DNA signals that alert the immune system.(00:13:01) Cancer's Evasion MechanismHow tumors destroy immune signals to hide from detection.(00:14:26) ENPP1 EnzymeIdentification of ENPP1 as the enzyme enabling immune evasion.(00:15:22) Balancing Immunity and SafetyRole of ENPP1 in autoimmunity and the challenge of targeting it safely.(00:19:30) ENPP1 InhibitorsDevelopment of molecules to block ENPP1 and enhance immune signaling.(00:24:55) Preclinical FindingsThe promising results against aggressive solid tumors in animal studies(00:28:05) From Lab to ClinicThe progress toward FDA approval and preparation for human testing.(00:31:04) Future In a MinuteRapid-fire Q&A: innovation, collaboration, and the outlook for cancer treatment.(00:33:14) Conclusion Connect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>>Twitter/X / Instagram / LinkedIn / Facebook Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Today, we're talking to Dr. David Darrow for a second time. Check out episode 30 for our first discussion. David is a neurosurgeon and assistant professor in the departments of neurosurgery and psychiatry at the University of Minnesota. Many of you will also know that he is a researcher and the primary investigator of the successful and ongoing E-Stand trial, which uses epidural stimulation and optimization protocols for delivering functional outcomes for the SCI community. We discussed the E-Stand trial, how it's progressing, and highlights from its now eight years of running. We also talk about the FDA and the quandary of determining what is meaningful in the eyes of research participants, as well as with regulators. And we get into spinal cord stimulation data sharing, the exciting horizon of combinatorial therapies, and much, much more. As you will hear on this call, David is a smart, innovative, forward-thinking ally of the SCI community. More info: https://u2fp.org/get-educated/curecast/episode-135.html
Send us a textIn this comprehensive episode, canna-lawyer Tom dives into the recent changes in federal hemp laws and their impact on the industry. Drawing from his extensive experience in the field, Tom provides an in-depth analysis of the new hemp regulations, including the redefinition of hemp, the inclusion of THCA, and the stringent guidelines for THC concentration. He also discusses the implications for hemp businesses, particularly in the context of banking and legal compliance.
In this second part of the conversation, Dr. Scott Sherr returns to unpack one of the most fascinating compounds in modern mitochondrial medicine — methylene blue. Once used as the first FDA-approved antimicrobial drug, methylene blue is now being rediscovered as a powerful mitochondrial optimizer that helps the body both produce and detoxify energy at the same time. Dr. Sherr breaks down how it enhances ATP production, improves focus, endurance, and recovery, and even helps with travel fatigue and brain fog. He explains how methylene blue works at the cellular level, why quality and dosing matter, and clears up common myths and controversies — including its relationship with nitric oxide, serotonin, and safety concerns. Whether you're an athlete, entrepreneur, or anyone seeking more consistent, sustainable energy, this episode will help you understand how to use methylene blue safely and effectively to support performance and longevity. Follow Scott @drscottsherr Follow Chase @chase_chewning ----- 00:01 What Is Methylene Blue? — A 150-year-old molecule repurposed for mitochondrial health 02:13 From Blue Jeans to Medicine — The strange evolution from textile dye to the first FDA-approved drug 04:48 How It Works — The only compound that helps your cells both make and detoxify energy 06:52 Cyanide Antidote — How methylene blue restores mitochondrial function, even in toxin exposure 09:05 Real-World Results — Patient stories of fatigue recovery and performance optimization 11:34 Who It's For — From chronic illness to high performers seeking clean energy 13:31 Performance & Recovery Benefits — Endurance, anaerobic performance, and muscle recovery 16:18 Recovering Faster, Training Harder — How methylene blue enhances oxygen use and heart rate recovery 18:20 How to Cycle It — When and how often to take methylene blue for best results 20:31 Travel & Jet Lag Protocols — How methylene blue acts like oxygen at altitude and in airplanes 23:29 Methylene Blue for the Everyday Person — Calm, clean energy without the crash 26:33 The Importance of Quality & Purity — How to identify pharmaceutical-grade methylene blue and avoid contaminants 27:57 What to Look for in a Supplement — USP grade, certificates of analysis, and testing standards 30:51 Counterfeit Supplements & Amazon Scams — Why most methylene blue products don't meet purity claims 33:54 How to Take It — Solubility, timing, and why troches work best 36:09 Stacking with Red Light Therapy — Synergy between methylene blue and photobiomodulation 39:10 Dosage Guidelines — How to titrate, start low, and find your personal sweet spot 42:08 Who Should Avoid It — Blood pressure medications, SSRIs, pregnancy, and other contraindications 43:48 Clearing Up the Controversy — Why experts disagree on nitric oxide and serotonin effects. 45:23 The Nitric Oxide Debate — How dose determines whether methylene blue helps or hinders 47:51 Blue Brain Myths & Social Media Clickbait — The truth about the "blue brain" narrative 49:30 Final Thoughts — Safe dosing, cycling, and the future of mitochondrial optimization ----- Episode resources: Part one "The #1 Thing Killing Your Mitochondra & How to Stop it Today" Watch and subscribe on YouTube Learn more at Troscriptions.com/everforward
In this episode, ARK's Cathie Wood and Brett Winton sit down with Sean McClain, Founder and CEO of AbSci, to explore how generative AI is reshaping drug discovery, development timelines, and clinical costs. Sean walks through real-world examples of AI-designed antibodies—such as AbSci's breakthrough HIV antibody and a regenerative treatment for hair loss—and explains how these platforms are helping unlock previously “undruggable” biology.They discuss AbSci's Phase 2-ready hair growth antibody (BS201), the company's partnerships with Caltech and AMD, and why the FDA's evolving embrace of AI could accelerate the end of animal testing. The conversation closes with a forward-looking discussion on the role of regenerative medicine in longevity—and why AI drug discovery might just pull biotech out of its multi-year bear market.Key Points From This Episode:(00:00:00) How AbSci uses generative AI to design antibodies from scratch(00:02:42) HIV, ion channels, and the promise of targeting "undruggable" biology(00:06:28) AbSci's BS201 drug for hair regrowth: mechanism, speed, and cost advantages(00:13:20) Clinical timeline: From concept to Phase 2 readout in 3.5 years(00:15:34) Bringing costs down: $100–150M vs. the industry average of $2.4B(00:17:36) Why AI enables “keys designed for specific locks” in drug targeting(00:22:58) What AbSci's models are trained on—and how prompts work in drug inference(00:25:32) The future of clinical testing: AI replacing animal models(00:36:43) Sarcopenia, strength loss, and regenerative approaches to aging(00:48:10) BS201 as a long-acting pulse therapy—and how it compares to transplants
In this episode, Psychedelic Medicine Podcast host, Dr. Lynn Marie Morski, provides the latest updates from the field of psychedelic medicine. Dr. Morski discusses the breakthrough therapy designation which a number of psychedelic compounds have received in the past few years, the most recent of which is BPL-003, a nasal spray formulation of 5-MeO-DMT. One of the exciting aspects of this new compound, Dr. Morski notes, is that it is shorter-acting than most serotonergic psychedelics—a feature which may make treatment with this substance less expensive and more accessible. Another exciting development is the COMPASS Pathways phase 3 trial of COMP360 psilocybin. Dr. Morski shares that the company believes they are nine to twelve months ahead of schedule, which means that if all goes well, this psilocybin compound could be approved for treatment resistant depression as early as sometime in 2027. She also discusses why the US FDA said they rejected MDMA for PTSD and what this governing body would like to see from subsequent research before reconsidering this decision. In closing, Dr. Morski shares excitement about the development of novel psychoplastogens—the non-hallucinogenic psychedelics—which may help bring many of the same healing benefits to populations currently unable to be served by the existing compounds under investigation. In this episode, you'll hear: Which psychedelics currently have breakthrough therapy designation and for which indications Details of recent ketamine research for inpatient depression care and why these results are not as negative as they may seem The current horizons of psychedelic research and what indications may soon be explored Sources of hope in the current state of psychedelic research and the legal landscape Quotes: "[BPL-003] showed rapid and durable antidepressant outcomes after a single dose. … here we have something that is under an hour [of psychedelic experience] for treatment resistant depression." [7:43] "Keeping patients blinded to whether or not they got the placebo or MDMA is a big focus that [the FDA] wanted to emphasize for these future phase 3 trials." [19:07] "I know we had a big setback last year. I think a lot of us thought by this time we'd be a year into MDMA being approved and we're not. However, there are so many things on the horizon that are worth being excited about." [23:48] Links: Psychedelic Medicine Podcast on Instagram Psychedelic Medicine Podcast on YouTube Jelovac A, McCaffrey C, Terao M, et al. "Serial Ketamine Infusions as Adjunctive Therapy to Inpatient Care for Depression: The KARMA-Dep 2 Randomized Clinical Trial" JAMA Psychiatry, 2025. Beckley Psytech Limited Phase 2 Trial: BPL-003 Efficacy and Safety in Treatment Resistant Depression COMPASS Pathways Phase 3 Trial: Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD Food and Drug Administration (FDA) Complete Response Letter (CRL) to Lykos Therapeutics, declining to approve MDMA-assisted therapy for Posttraumatic Stress Disorder Psychedelic Alpha Psychedelic Drug Development Bullseye Chart Psychedelic Medicine Association Porangui
Episode 320: The Truth About Red Light Therapy with Steve Marchese, CEO of LightStimGuest: Steve MarcheseWebsite: www.LightStim.comExclusive Code: Use THRIVE for 10% off your order at LightStim.comEpisode OverviewIn this episode, Jay sits down with Steve Marchese, CEO of LightStim, the largest manufacturer of red light therapy devices in the United States ~ trusted by over 50,000 professionals and more than one million consumers worldwide.If you've ever been curious (or skeptical) about red light therapy, this conversation is your inside look at what's real, what's hype, and what actually moves the needle for recovery, performance, and longevity.Steve pulls back the curtain on how LightStim became the gold standard in LED technology ~ from FDA-cleared handhelds to full-body wellness beds and how the company built its reputation on science, safety, and results.What You'll LearnThe real science behind red and infrared light therapy ~ how it impacts mitochondria, ATP production, and circulation.Why the FTC recently issued warnings to the health and wellness industry about misleading claims, and what you should know before you buy any red light device.The difference between a legitimate medical-grade LED system and the cheap panels flooding social media.The LightStim story ~ how a family's personal experience led to pioneering the modern red light movement.Why LightStim's FDA-cleared devices set the standard for safety, efficacy, and long-term results.Practical takeaways for fitness, recovery, skin health, and performance and how to use red light therapy correctly for real benefits.Key TakeawaysNot all red light is created equal. Wavelength, intensity, and FDA clearance matter.Beware of marketing myths. Steve explains how to separate facts from internet fiction.LightStim's approach is different. Backed by science, engineered for results, and built in the USA.Performance is cellular. When your mitochondria perform better, you perform better.Connect with LightStimWebsite: www.LightStim.comInstagram: @LightStimUse code THRIVE for 10% off your purchaseJay's TakeawayThis episode is a wake-up call for anyone who's serious about optimizing recovery and performance. The red light therapy industry is booming, but few companies are doing it right and LightStim is leading the charge with integrity, science, and results.If you want to feel better, recover faster, and perform at your peak, this conversation is a must-listen.
The House races to vote on a resolution that could end the government shutdown, the FDA removes "black box" warnings for hormone replacement therapy drugs, and we look at the role media bias played in shaping Americans' views on the shutdown. Get the facts first with Morning Wire. - - - Wake up with new Morning Wire merch: https://bit.ly/4lIubt3 - - - Today's Sponsors: Boll & Branch - Get 25% off sitewide plus free shipping and extended returns at https://bollandbranch.com/WIRE and use code WIRE Shopify - Go to https://Shopify.com/morningwire to sign up for your $1-per-month trial period and upgrade your selling today. Beam - Go to https://shopbeam.com/WIRE, use code WIRE, and get up to 50% off during Beam's Cyber Sale. - - - Privacy Policy: https://www.dailywire.com/privacy morning wire,morning wire podcast,the morning wire podcast,Georgia Howe,John Bickley,daily wire podcast,podcast,news podcast Learn more about your ad choices. Visit podcastchoices.com/adchoices
Dave Rubin of "The Rubin Report" talks about "The View's" Sunny Hostin trying to shame Democrat John Fetterman live on-air for voting to end the government shutdown only to have it blow up in her face; CNN's Harry Enten showing shocking new polling data of who is most likely to replace Chuck Schumer; BBC CEO Deborah Turness resigning from her post after Donald Trump's lawsuit over the BBC's January 6th documentary was exposed for having purposely misleading edits to defame Donald Trump; Piers Morgan apologizing to Novak Djokovic on "Piers Morgan Uncensored" for his attack on him for being unvaccinated during the COVID pandemic; Russell Brand's appearance on "Real Time with Bill Maher," where he roasted MSNBC's John Heilemann for media bias; Donald Trump's tense exchange with Fox News' Laura Ingraham over H-1B visas and Chinese immigrants who take the slots in America's universities that could go to Americans; Palmer Luckey explaining to Shawn Ryan how H-1B visas are abused in Silicon Valley; World War II veteran Alec Penstone telling "Good Morning Britain" why he regrets his sacrifice to the UK on Remembrance Day; and much more. WATCH the MEMBER-EXCLUSIVE segment of the show here: https://rubinreport.locals.com/ Check out the NEW RUBIN REPORT MERCH here: https://daverubin.store/ ---------- Today's Sponsors: Morgan & Morgan - Morgan & Morgan is America's Largest Injury Law Firm, with over 1,000 attorneys operating in all 50 states. Go to: https://ForThePeople.com/Rubin Juvent - Stop joint pain and stiffness with the Juvent Micro-Impact Platform. In the US, the Juvent device is considered investigational for the treatment of osteoporosis or improvement/maintenance of bone mineral density. Our claims have not been reviewed or cleared by the FDA to treat any disease or condition. The JUVENT® Micro-Impact Platform® is registered as a Class I medical device for exercise and rehabilitation." Go to http://Juvent.com/RUBIN and use the code RUBIN to save $300 on your own Juvent. Tax Network USA - If you owe back taxes or have unfiled returns, don't let the government take advantage of you. Whether you owe a few thousand or a few million, they can help you. Call 1(800)-958-1000 for a private, free consultation or Go to: https://tnusa.com/dave
A mainstream “hit piece” targeting HHS Secretary Robert F. Kennedy Jr. for linking Tylenol to autism is backfiring. Newly uncovered internal emails reportedly show the drug's manufacturer acknowledging concerns about prenatal Tylenol use and neurodevelopmental disorders. Now, Texas Attorney General Ken Paxton is suing major pharma companies for deceptively marketing Tylenol to pregnant mothers—and ICAN has petitioned the FDA to add pregnancy warnings to acetaminophen labels.Become a supporter of this podcast: https://www.spreaker.com/podcast/the-highwire-with-del-bigtree--3620606/support.
Angel Studios https://Angel.com/HermanJoin the Angel Guild today and know you are not just watching, you're helping make bold, faith driven stories like Disciples in the Moonlight possible. That's Angel.com/HermanRenue Healthcare https://Renue.Healthcare/ToddYour journey to a better life starts at Renue Healthcare. Visit https://Renue.Healthcare/Todd Bulwark Capital https://KnowYourRiskPodcast.comRegister now for the free Review/Preview Webinar November 20th 3:30pm Pacific, schedule your free Know Your Risk Portfolio Review, and subscribe to Zach's Daily Market Recap at (SLOW) Know Your Risk Podcast dot com. Alan's Soaps https://www.AlansArtisanSoaps.comUse coupon code TODD to save an additional 10% off the bundle price.Bonefrog https://BonefrogCoffee.com/toddThe new GOLDEN AGE is here! Use code TODD at checkout to receive 10% off your first purchase and 15% on subscriptions.SNAP Fraud Should Be GREAT for Jesus & Families // Should Life-Saving be Legal? // Yeah, but WHICH Jesus?Episode Links:Nationwide Fraud of SNAP and EBT Program. Arrests being made where businesses are caught on hidden camera paying .50 cents on the dollar for people's SNAP benefits cardsIllegals accused of stealing more than $150,000 in SNAP benefits in Ohio. Ohio has reported to losing $17M in SNAP benefits from fraud since 2023. Biden's invaders are stealing taxpayer funded resources from AmericansJUST IN: South Carolina woman Briana Simmons arrested and facing charges for allegedly defrauding taxpayer funded SNAP program of nearly $57K. But Democrats said this never happens…'Dilbert' creator's desperate plea shines spotlight on alternative prostate cancer drug What to know about Pluvicto, the FDA-approved prostate cancer drug gaining national attentionBREAKING: Legendary author Scott Adams just revealed that Donald Trump Jr., HHS Secretary RFK Jr., and CMS Administrator Dr. Oz personally called to make sure he gets the help and treatment he needs to help him fight cancer.
© 2020-2025 Ivy Podcast Discovery LLC
